Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention
Abstract
:1. Introduction
2. Insert Platform as a Topical Drug Delivery System
3. Development of On-Demand Topical TAF/EVG Inserts for HIV Prevention
4. Acceptability Assessment of Placebo and ARV-Containing Inserts
5. Preclinical Testing of TAF/EVG Inserts Shows Safety and High Efficacy When Applied before and after Virus Challenge
6. Clinical Testing of TAF/EVG Inserts Demonstrates Safety, Pharmacokinetics, and Pharmacodynamics Profiles Compatible with Protection against HIV
7. Summary and Future Directions for TAF/EVG Inserts
8. Patents
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- UNAIDS HIV Prevention 2025 Roadmap. Available online: https://www.unaids.org/en/resources/documents/2022/prevention-2025-roadmap (accessed on 7 December 2023).
- Stover, J.; Rosen, J.E.; Carvalho, M.N.; Korenromp, E.L.; Friedman, H.S.; Cogan, M.; Deperthes, B. The case for investing in the male condom. PLoS ONE 2017, 12, e0177108. [Google Scholar] [CrossRef]
- Hanscom, B.; Janes, H.E.; Guarino, P.D.; Huang, Y.; Brown, E.R.; Chen, Y.Q.; Hammer, S.M.; Gilbert, P.B.; Donnell, D.J. Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. J. Acquir. Immune Defic. Syndr. 2016, 73, 606–608. [Google Scholar] [CrossRef]
- Haire, B.G. Preexposure prophylaxis-related stigma: Strategies to improve uptake and adherence—A narrative review. HIV/AIDS-Res. Palliat. Care 2015, 7, 241–249. [Google Scholar] [CrossRef]
- Prather, C.; Jeon, C. Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. Am. J. Health Syst. Pharm. 2022, 79, 1898–1905. [Google Scholar] [CrossRef]
- Bares, S.H.; Scarsi, K.K. A new paradigm for antiretroviral delivery: Long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr. Opin. HIV AIDS 2022, 17, 22–31. [Google Scholar] [CrossRef] [PubMed]
- Andrews, C.D.; Heneine, W. Cabotegravir long-acting for HIV-1 prevention. Curr. Opin. HIV AIDS 2015, 10, 258–263. [Google Scholar] [CrossRef] [PubMed]
- Noret, M.; Balavoine, S.; Pintado, C.; Siguier, M.; Brun, A.; Bauer, R.; Loze, B.; Leplatois, A.; Aslan, A.; Moudachirou, K.; et al. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: Experience from a hospital-based clinic in France. AIDS 2018, 32, 2161–2169. [Google Scholar] [CrossRef] [PubMed]
- Reyniers, T.; Nostlinger, C.; Laga, M.; De Baetselier, I.; Crucitti, T.; Wouters, K.; Smekens, B.; Buyze, J.; Vuylsteke, B. Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project. J. Acquir. Immune Defic. Syndr. 2018, 79, 186–194. [Google Scholar] [CrossRef]
- Vaccher, S.J.; Gianacas, C.; Templeton, D.J.; Poynten, I.M.; Haire, B.G.; Ooi, C.; Foster, R.; McNulty, A.; Grulich, A.E.; Zablotska, I.B.; et al. Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project. Front. Public Health 2017, 5, 341. [Google Scholar] [CrossRef] [PubMed]
- Baeten, J.M.; Hendrix, C.W.; Hillier, S.L. Topical Microbicides in HIV Prevention: State of the Promise. Annu. Rev. Med. 2020, 71, 361–377. [Google Scholar] [CrossRef]
- Nel, A.; van Niekerk, N.; Kapiga, S.; Bekker, L.G.; Gama, C.; Gill, K.; Kamali, A.; Kotze, P.; Louw, C.; Mabude, Z.; et al. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. N. Engl. J. Med. 2016, 375, 2133–2143. [Google Scholar] [CrossRef]
- Peet, M.M.; Agrahari, V.; Anderson, S.M.; Hanif, H.; Singh, O.N.; Thurman, A.R.; Doncel, G.F.; Clark, M.R. Topical Inserts: A Versatile Delivery Form for HIV Prevention. Pharmaceutics 2019, 11, 374. [Google Scholar] [CrossRef] [PubMed]
- Derby, N.; Lal, M.; Aravantinou, M.; Kizima, L.; Barnable, P.; Rodriguez, A.; Lai, M.; Wesenberg, A.; Ugaonkar, S.; Levendosky, K.; et al. Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo. Nat. Commun. 2018, 9, 3881. [Google Scholar] [CrossRef]
- Hoang, T.; Date, A.A.; Ortiz, J.O.; Young, T.W.; Bensouda, S.; Xiao, P.; Marzinke, M.; Rohan, L.; Fuchs, E.J.; Hendrix, C.; et al. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema. Eur. J. Pharm. Biopharm. 2019, 138, 23–29. [Google Scholar] [CrossRef]
- Li, J.; Regev, G.; Patel, S.K.; Patton, D.; Sweeney, Y.; Graebing, P.; Grab, S.; Wang, L.; Sant, V.; Rohan, L.C. Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel. Pharmaceutics 2019, 12, 1. [Google Scholar] [CrossRef] [PubMed]
- Patel, S.K.; Agashe, H.; Patton, D.L.; Sweeney, Y.; Beamer, M.A.; Hendrix, C.W.; Hillier, S.L.; Rohan, L.C. Tenofovir vaginal film as a potential MPT product against HIV-1 and HSV-2 acquisition: Formulation development and preclinical assessment in non-human primates. Front. Reprod. Health 2023, 5, 1217835. [Google Scholar] [CrossRef]
- Dobard, C.W.; Peet, M.M.; Nishiura, K.; Holder, A.; Dinh, C.; Mitchell, J.; Khalil, G.; Pan, Y.; Singh, O.N.; McCormick, T.J.; et al. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques. EBioMedicine 2022, 86, 104361. [Google Scholar] [CrossRef] [PubMed]
- Makarova, N.; Singletary, T.; Peet, M.M.; Mitchell, J.; Holder, A.; Dinh, C.; Agrahari, V.; Mendoza, M.; Pan, Y.; Heneine, W.; et al. Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques. EBioMedicine 2022, 86, 104338. [Google Scholar] [CrossRef]
- Singh, O.N.; Mccormick, T.J.; Agrahari, V.; Peet, M.M.; Clark, M.R.; Schwartz, J.; Doncel, G.F. Pharmaceutical Compositions and Methods of Making on Demand Solid Dosage Formulations. U.S. Patent 20210379089 A1, 9 December 2021. [Google Scholar]
- Clark, M.R.; Peet, M.M.; Davis, S.; Doncel, G.F.; Friend, D.R. Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention. Pharmaceutics 2014, 6, 616–631. [Google Scholar] [CrossRef]
- Mauck, C.K.; Thurman, A.; Keller, M.; Archer, D.F.; Kimble, T.; Kashuba, A.; Sykes, C.; Friend, D.; Schwartz, J.L.; Doncel, G.F. Pharmacokinetics of Tenofovir and Emtricitabine Delivered by Vaginal Tablets. Presented at the Conference on Retroviruses and Opportunitis Infections (CROI), Seattle, WA, USA, 23–26 February 2015. [Google Scholar]
- Littlefield, S.; Zhang, W.; Schwartz, J.; Clark, M.; Thurman, A.; Archer, D.; Mauck, C.; Linton, K.; McCormick, T.; Jacot, T.; et al. Clinical performance, acceptability and optimization of fast dissolve vaginal inserts designed for HIV prevention: Results from two clinical studies. In Proceedings of the in Conference Presentation at HIV Research for Prevention (HIV R4P), Chicago, IL, USA, 18 October 2016. [Google Scholar]
- Ouattara, A.; Kerr, B.; Abdelmawla, F.; Anderson, P.; Clark, M.; Doncel, G.F. Time of addition studies of elvitegravir/TFV prodrug combinations demonstrate extended window of prophylactic activity in cells and tissue models. In Proceedings of the In Conference Presentation at HIV Research for Prevention (HIV R4P), Chicago, IL, USA, 17–21 October 2016. [Google Scholar]
- Chen, H.; Aburub, A.; Sun, C.C. Direct Compression Tablet Containing 99% Active Ingredient-A Tale of Spherical Crystallization. J. Pharm. Sci. 2019, 108, 1396–1400. [Google Scholar] [CrossRef]
- Hill, A.M.; Barber, M.J.; Gotham, D. Estimated costs of production and potential prices for the WHO Essential Medicines List. BMJ Glob. Health 2018, 3, e000571. [Google Scholar] [CrossRef] [PubMed]
- Bauermeister, J.A.; Downs, J.S.; Krakower, D.S. PrEP Product Acceptability and Dual Process Decision-Making Among Men Who Have Sex with Men. Curr. HIV/AIDS Rep. 2020, 17, 161–170. [Google Scholar] [CrossRef] [PubMed]
- Carballo-Dieguez, A.; Giguere, R.; Lentz, C.; Dolezal, C.; Fuchs, E.J.; Hendrix, C.W. Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche. AIDS Behav. 2019, 23, 1484–1493. [Google Scholar] [CrossRef] [PubMed]
- Luecke, E.H.; Cheng, H.; Woeber, K.; Nakyanzi, T.; Mudekunye-Mahaka, I.C.; van der Straten, A.; Team, M.-D.S. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study. J. Int. AIDS Soc. 2016, 19, 20875. [Google Scholar] [CrossRef]
- Pines, H.A.; Gorbach, P.M.; Weiss, R.E.; Hess, K.; Murphy, R.; Saunders, T.; Brown, J.; Anton, P.A.; Cranston, R.D. Acceptability of potential rectal microbicide delivery systems for HIV prevention: A randomized crossover trial. AIDS Behav. 2013, 17, 1002–1015. [Google Scholar] [CrossRef]
- Tingler, R.C.; Connochie, D.; Bauermeister, J.A. Rectal Douching and Microbicide Acceptability among Young Men who Have Sex with Men. AIDS Behav. 2020, 24, 1414–1421. [Google Scholar] [CrossRef]
- Montgomery, E.T.; Beksinska, M.; Mgodi, N.; Schwartz, J.; Weinrib, R.; Browne, E.N.; Mphili, N.; Musara, P.; Jaggernath, M.; Ju, S.; et al. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: The Quatro Clinical Crossover Study. J. Int. AIDS Soc. 2019, 22, e25283. [Google Scholar] [CrossRef]
- Thurman, A.R.; Ouattara, L.A.; Yousefieh, N.; Anderson, P.L.; Bushman, L.R.; Fang, X.; Hanif, H.; Clark, M.; Singh, O.; Doncel, G.F. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir. Front. Cell Infect. Microbiol. 2023, 13, 1130101. [Google Scholar] [CrossRef]
- Riddler, S.A.; Kelly, C.; Hoesley, C.; Ho, K.; Piper, J.; Edick, S.; Heard, F.; Jiao, Y.; Doncel, G.F.; Johnson, S.; et al. Safety and PK/PD of a Tenofovir alafenamide/Elvitegravir insert administrated rectally. In Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA USA, 19–22 February 2023. [Google Scholar]
- Musara, P.; Milford, C.; Shapley-Quinn, M.K.; Weinrib, R.; Mutero, P.; Odoom, E.; Mgodi, N.M.; Chirenje, Z.M.; Hanif, H.; Clark, M.R.; et al. Preferences and Acceptability of Vaginal Delivery Forms for HIV Prevention Among Women, Male Partners and Key Informants in South Africa and Zimbabwe: Qualitative Findings. AIDS Behav. 2021, 25, 124–138. [Google Scholar] [CrossRef] [PubMed]
- Bauermeister, J.A.; Dominguez Islas, C.; Jiao, Y.; Tingler, R.; Brown, E.; Zemanek, J.; Giguere, R.; Balan, I.; Johnson, S.; Macagna, N.; et al. A randomized trial of safety, acceptability and adherence of three rectal microbicide placebo formulations among young sexual and gender minorities who engage in receptive anal intercourse (MTN-035). PLoS ONE 2023, 18, e0284339. [Google Scholar] [CrossRef] [PubMed]
- Doncel, G.F.; Chandra, N.; Fichorova, R.N. Preclinical assessment of the proinflammatory potential of microbicide candidates. J. Acquir. Immune Defic. Syndr. 2004, 37 (Suppl. S3), S174–S180. [Google Scholar] [CrossRef] [PubMed]
- Eckstein, P.; Jackson, M.C.; Millman, N.; Sobrero, A.J. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J. Reprod. Fertil. 1969, 20, 85–93. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Lerma, J.G.; McNicholl, J.M.; Heneine, W. The predictive value of macaque models of preexposure prophylaxis for HIV prevention. Curr. Opin. HIV AIDS 2022, 17, 179–185. [Google Scholar] [CrossRef] [PubMed]
- Makarova, N.; Singletary, T.; Peet, M.M.; Mitchell, J.; Bachman, S.; Holder, A.; Dinh, C.; Lipscomb, J.; Agrahari, V.; Mendoza, M.; et al. Extended post-exposure protection against vaginal SHIV infection with tenofovir alafenamide fumarate/elvitegravir inserts in macaques. J. Infect. Dis. 2023, jiad599. [Google Scholar] [CrossRef] [PubMed]
- Dobard, C.W.; Sharma, S.; Cong, M.E.; West, R.; Makarova, N.; Holder, A.; Pau, C.P.; Hanson, D.L.; Novembre, F.J.; Garcia-Lerma, J.G.; et al. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques. Retrovirology 2015, 12, 69. [Google Scholar] [CrossRef]
- Ramanathan, S.; Mathias, A.A.; German, P.; Kearney, B.P. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin. Pharmacokinet. 2011, 50, 229–244. [Google Scholar] [CrossRef]
- Dobard, C.; Sharma, S.; Martin, A.; Pau, C.P.; Holder, A.; Kuklenyik, Z.; Lipscomb, J.; Hanson, D.L.; Smith, J.; Novembre, F.J.; et al. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J. Virol. 2012, 86, 718–725. [Google Scholar] [CrossRef]
- Andrei, G.; Gillemot, S.; Topalis, D.; Snoeck, R. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. J. Infect. Dis. 2018, 217, 790–801. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Peet, M.M.; Agrahari, V.; Clark, M.R.; Doncel, G.F. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention. Pharmaceutics 2024, 16, 348. https://doi.org/10.3390/pharmaceutics16030348
Peet MM, Agrahari V, Clark MR, Doncel GF. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention. Pharmaceutics. 2024; 16(3):348. https://doi.org/10.3390/pharmaceutics16030348
Chicago/Turabian StylePeet, M. Melissa, Vivek Agrahari, Meredith R. Clark, and Gustavo F. Doncel. 2024. "Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention" Pharmaceutics 16, no. 3: 348. https://doi.org/10.3390/pharmaceutics16030348